NCT05357612RecruitingPhase 4
Characterization of the Serotonin 2A Receptor Selective PET Tracer [18F]MH.MZ in Patients With Neurodegenerative Diseases
Source: ClinicalTrials.gov · Last updated 7 Aug 2026
Brief summary (registry, in English)
It is hypothesize that patients with clinically diagnosed neurodegenerative diseases will have significantly different receptor occupancy of 5HT2A receptors compared to a healthy age/sex-matched control group. This will be tested by measuring 5HT2A receptor density using the PET radioligand (R)-\[18F\]MH.MZ in both populations.
- Status (registry)
- Recruiting
- Phase (registry)
- Phase 4
- Study type
- Interventional
- Enrollment
- 75 (estimated)
- First submitted
- 20 Apr 2022
- Start date
- 23 Jan 2023
- Primary completion date
- Jun 2027
- Lead sponsor
- Vanderbilt University Medical Center
- Diseases
- Parkinson disease
- NCT number
- NCT05357612
What you commit to
- Study type: Interventional · Phase 4
- Planned participants: 75
- From 23 Jan 2023 to the primary completion date, Jun 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Prior stroke or other uncontrolled serious neurological or medical illness
- Use of serotonergic medications in the last 6 weeks
- For PD Participants: current or prior use of pimavanserin
Other illness
- psychosis due to a metabolic, toxic, or primary psychiatric disease
Other
- Contra-indication or inability to tolerate MRI scan
- Incapable of providing independent consent.
- Pregnant or breastfeeding women
- Deemed unable to complete neurocognitive testing
- Use of antipsychotics in the last 2 weeks
Who the study is looking for
- Patient arm - clinical diagnosis of Parkinson disease, diffuse Lewy body disease, multiple systems atrophy, Huntington's Disease, Frontotemporal Dementia, and other variants
- Healthy arm - age and gender matched to patient arm
- Psychosis (presence of hallucinations or delusions) starting after the diagnosis of Parkinson's disease, occurring at least weekly for 4 weeks, severe enough to warrant treatment.
- Study partner available for study visits
Age in the registry: 50 years to 85 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Vanderbilt University Medical Center Coordinator of this site? Confirm its status | Nashville | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.